YMC-Triart C18 for separation of 11 common cannabinoids

YMC-Triart C18 for separation of 11 common cannabinoids

Overview

  • Post By :

  • Source: YMC Europe GmbH

  • Date: 30 Jan,2021

Until recently, cannabis and its derivatives were widely restricted under legislation which stated they had no medical value and carried a substantial risk of misuse. Policy is rapidly changing, and cannabis can now be prescribed for medicinal use in many countries across Europe. This provides important new opportunities for treating patients although these need to be weighed up against potential risks.

Several different medicinal products exist, with contrasting mechanisms of action, efficacy, and safety. Use of these products may increase as new evidence arises and policy changes occur. Certified medicinal cannabis is currently used for the treatment of a number of conditions, including multiple sclerosis, epilepsy, neuropathic pain, arthritis, depression, anxiety disorders, sleep disorders, psychosis, glaucoma and Tourette’s syndrome. It is also used for the relief of symptoms such as nausea and vomiting as a result of chemotherapy, and appetite stimulation in patients suffering from HIV and AIDS.

For the full method details please download the application note. Visit our homepage or download the YMC-Triart brochure 

About Author